Article

Dr. Serena Wong Discusses Cognitive Dysfunction After Cancer

Oncologist Serena Wong, of Rutgers Cancer Institute of New Jersey, reassures patients suffering from cognitive dysfunction, or chemobrain, that they're not alone and there is support.

Oncologist Serena Wong, of Rutgers Cancer Institute of New Jersey, wants to lets patients suffering from cognitive dysfunction, or chemobrain, know that they're not alone.

"It was actually in the 1980s when we were finding that in support groups, a lot of cancer survivors were talking about having trouble with memory, having trouble concentrating. and then people started sharing their experiences," she says. "We started realizing that this is something we needed to pay attention to."

In the 1990s, the scientific community really began studying the issue, she says.

Wong suggests patients be patient with themselves, allow extra time to complete multiple tasks, and understand that going through therapy takes a toll. "You're not going to bounce back immediately, and that can be a little bit frustrating," she says.

She also recommends staying active and exercising to help fatigue, energy and cognitive function.

Related Videos
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker